

Claim 7, line 2: Delete "2,3-dihydrobenzofuran-5-yl, chroman-6-yl,".

Claim 12, line 1: Delete "Z is N and".

Claim 16, line 1: Delete "Z is N and".

Claim 24, line 1: Change "23," to -- 1, --.

Claim 25, line 1: Change "23," to -- 1, --.

Claim 28, line 1: Change "23," to -- 1, --.

R E M A R K S

Amendments

The above amendments are submitted for purposes of furthering prosecution and to obtain an early allowance of the instant application. Entry thereof is respectfully requested. Submission of these amendments is not to be construed as an acquiescence to any ground of rejection.

In the Office Action of October 25, 1995, the examiner indicated that claims 16, 24, 25 and 28 recited allowable subject matter. While claim 12 was not indicated as reciting allowable subject matter, it is stated in the Office Action that "R¹ as ... benzofuranyl ... is not suggested by the combined teachings of Boettcher and Perregaard...." See page 4, lines 4-6, of the October 25, 1995, Office Action.

Claim 1, as amended above, corresponds to the combined scope of claims 12, 24, 25 and 28. Therefore, it is respectfully submitted that the above amendments place the application in condition for allowance. Entry of the amendments and allowance of the instant application is again respectfully requested.

Improper Markush Rejection

As noted above, the amendments to the claims is not to be construed as an acquiescence to any ground of rejection. In any